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Mutations in OPA1, a dynamin-related GTPase involved in mitochondrial fusion, cristae organization and con-
trol of apoptosis, have been linked to non-syndromic optic neuropathy transmitted as an autosomal-dominant
trait (DOA).We here report on eight patients from six independent families showing that mutations in the OPA1
gene can also be responsible for a syndromic form of DOA associated with sensorineural deafness, ataxia,
axonal sensory-motor polyneuropathy, chronic progressive external ophthalmoplegia and mitochondrial myo-
pathy with cytochrome c oxidase negative and Ragged Red Fibres. Most remarkably, we demonstrate that
these patients all harboured multiple deletions of mitochondrial DNA (mtDNA) in their skeletal muscle, thus
revealing an unrecognized role of the OPA1protein inmtDNA stability.The fiveOPA1mutations associated with
these DOA‘plus’ phenotypes were allmis-sense pointmutations affecting highly conserved amino acid positions
and the nuclear genes previously known to inducemtDNAmultiple deletions such as POLG1, PEO1 (Twinkle) and
SLC25A4 (ANT1) were ruled out.Our results show that certainOPA1mutations exert a dominant negative effect
responsible for multi-systemic disease, closely related to classical mitochondrial cytopathies, by a mechanism
involving mtDNA instability.
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Mitochondrial disorders can be due to genetic defects in
both the small mitochondrial double-stranded circular
genome (mtDNA) and the nuclear DNA (DiMauro and
Schon, 2003). A good example of this double genetic
determination is represented by the two most frequent non-
syndromic hereditary optic neuropathies, Leber’s hereditary
optic neuropathy (LHON; OMIM#535000) and dominant
optic atrophy (DOA; OMIM#165500). LHON is due, in the
large majority of worldwide cases, to one of three mtDNA
point mutation at positions 11778/ND4, 3460/ND1 and
14484/ND6, all affecting different subunits of complex I
(Carelli et al., 2004). DOA, in about 60–70% of cases, is
due to mutations in the nuclear gene encoding for the
OPA1 protein (Alexander et al., 2000; Delettre et al., 2000;
Cohn et al., 2007), a dynamin-related GTPase targeted to
mitochondria, which locates mostly on the mitochondrial
inner membrane (Delettre et al., 2002; Olichon et al., 2006).
OPA1 has been involved in multiple functions, the key role
being the fusion of mitochondria and thus the mitochon-
drial network organization (Olichon et al., 2006). Further
OPA1 functions are oxidative phosphorylation (OXPHOS)
and membrane potential maintenance (Olichon et al., 2003;
Lodi et al., 2004; Amati-Bonneau et al., 2005), as well as
cristae organization and control of apoptosis through the
compartimentalization of cytochrome c (Olichon et al.,
2003; Frezza et al., 2006).
The large majority of mutations in the OPA1 gene
described to date are predicted to lead to a truncated
protein and to haploinsufficiency (see http://lbbma.univ-
angers.fr) (Ferre et al., 2005). These mutations are
invariably associated with a non-syndromic, slowly pro-
gressive form of optic neuropathy, as originally described
by Kjer (1959). Classic DOA usually begins before 10 years
of age, with a large variability in the severity of clinical
expression, which may range from non-penetrant unaf-
fected cases up to very severe, early onset cases, even within
the same family carrying the same molecular defect
(Delettre et al., 2002; Carelli et al., 2004; Olichon et al.,
2006; Cohn et al., 2007). However, there is at least one clear
example standing out of this paradigm. This is a mutation
in the OPA1 gene, i.e. the c.1334G4A leading to p.R445H
amino acid change, being associated with a syndromic form
of optic neuropathy and sensorineural deafness (Amati-
Bonneau et al., 2003; Shimizu et al., 2003), and in some of
the reported cases with chronic progressive external
ophthalmoplegia (CPEO), ptosis and myopathy (Treft
et al., 1984; Meire et al., 1985; Payne et al., 2004).
CPEO, isolated or variably associated with a wider
syndromic clinical expression, is the most frequent feature
of mitochondrial myopathy and has a heterogeneous
genetic basis, again driven by both primary defects in the
mtDNA, i.e. single deletions and point mutations (DiMauro
and Schon, 2003), or by mutations in nuclear genes
resulting in multiple deletions of mtDNA (Zeviani et al.,
1989). At least four nuclear genes are now known to be
involved in CPEO associated with mtDNA multiple
deletions and autosomal recessive or dominant inheritance.
These are POLG1 (Van Goethem et al., 2001), the enzyme
replicating mtDNA, the mitochondrial replicative DNA
helicase Twinkle (PEO1) (Spelbrink et al., 2001), the heart/
muscle-specific adenine nucleotide translocator ANT1
(SLC25A4) (Kaukonen et al., 2000), and finally the
thymidine phosphorylase (TP) involved in the nucleoside
pool maintenance (Nishino et al., 1999). Among these
genes, mutations in at least two of them, i.e. POLG1 and
TP, may present with a combination of deletions and
depletion of mtDNA in skeletal muscle (Hirano et al., 2004;
Hudson and Chinnery, 2006).
The association of CPEO and mitochondrial myopathy
with optic atrophy is not frequent (Treft et al., 1984; Meire
et al., 1985) and never reported as due to mutations in the
above-mentioned genes. Thus, the clinical phenotype asso-
ciated with the OPA1/R445H mutation is somehow a novel
combination bridging autosomal-dominant CPEO and DOA
(Payne et al., 2004). Recent studies showed that the
biochemical phenotype of the OPA1/R445H mutation
consists in a defective OXPHOS in fibroblasts (Amati-
Bonneau et al., 2005). A defect in muscle bioenergetic
efficiency was also documented by MR spectroscopy (MRS)
in patients with the c.2708delTTAG microdeletion and classic
DOA (Lodi et al., 2004). Furthermore, slight reduction of
mtDNA copy number was reported in blood cells from DOA
patients (Kim et al., 2005), overall supporting the notion that
OPA1 may be involved in control of mtDNA content and
ultimately in OXPHOS efficiency.
We here report the association of different mis-sense
point mutations in the OPA1 gene in six families affected
with ‘plus’ phenotypes of optic atrophy and wider
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neuromuscular involvement including sensorineural deaf-
ness, cerebellar ataxia, axonal sensory-motor polyneuro-
pathy and mitochondrial myopathy frequently complicated
by CPEO. Most remarkably we provide evidence that
multiple deletions of mtDNA are accumulated in the
skeletal muscle of these patients, thus revealing an
unrecognized role of the OPA1 protein in maintaining
mtDNA integrity.
Patients and methods
Case reports
We here present the clinical histories of eight patients belonging to
the six families investigated (Fig. 1) and a summary of the clinical
and laboratory findings is reported in Table 1.
Case 1 (Family 1, I-2)
This family is fully described elsewhere and we here detail again
the clinical histories of the two affected subjects (Liguori et al., in
press). The proband is a 38-year-old man from Italy who was
noted for poor vision at 4 years of age. At 6 years of age a rapid
deterioration of his visual acuity led this patient to legal blindness.
At 9 years of age he also suffered a progressive hearing loss
needing acoustic prosthesis. At 30 years of age he developed gait
difficulties with frequent falls. We observed this patient for the
first time when he was 38 years old and his neurological exam
showed bilateral ophthalmoplegia and optic atrophy, severe
deafness, pes cavus, hypopallestesia at lower limbs, weak deep
tendon reflexes, positive Romberg sign and ataxic gait. Laboratory
investigations showed mild elevation of AST (45U/l, normal value
538) and ALT (65U/l, normal value541). Serum lactic acid after
standardized exercise was abnormally elevated (54.5mg/dl, normal
value 522). Muscle biopsy was positive for Ragged Red Fibres
(RRFs) and cytochrome c oxidase (COX) negative fibres (Fig. 2,
panels A, B and C). Electron microscopy of skeletal muscle
showed mitochondria with morphologically abnormal cristae and
accumulation of lipid droplets. Nerve conduction studies revealed
a mild sensory-motor axonal neuropathy. Somatosensorial evoked
potentials (SEPs) showed absent cortical responses from the lower
limbs and increased latencies from the upper limbs, suggestive of a
posterior column involvement. Motor evoked potentials (MEPs)
were normal. Pattern visual evoked potentials (PVEPs) showed
absent cortical responses bilaterally, whereas electroretinogram was
unremarkable. Brainstem auditory evoked potentials (BAEPs)
showed absent responses on left ear and increased latencies of
the IV and V response with absence of II and III response on right
ear. Audiometric exam showed a severe bilateral sensorineural
hearing loss. A brain MRI showed variable degrees of atrophy
affecting cerebral cortex, brainstem and cerebellum (Fig. 3,
panel A). Bilateral hypointensity of basal ganglia was detected at
the gradient echo MRI scan, which at CT scan was compat-
ible with bilateral calcifications (Fig. 3, panels B and C).
Electrocardiogram (EKG) was normal.
Fig. 1 Genealogical trees of the families investigated. Arrows indicate the probands of each pedigree, for which geographic origin and
the OPA1mis-sense point mutation, exon, and amino acid change are also provided. Asterisks indicate the individuals for which a clinical
history has been provided in the text.With the exception of Family 3, which is a sporadic case with a de novo mutation, all the other
families showed a pattern compatible with autosomal-dominant inheritance.
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Case 2 (Family 1, II-1)
This 7-year-old girl is the only daughter of the proband of Family
1, being born by caesarean delivery of non-consanguineous
parents. She had initial feeding difficulties and a slight delay in
her motor and language development. At 6 years of age she was
noted to have difficulties in watching the television. At this time a
marked pallor of the optic disc was reported and an audiometric
exam revealed a sensorineural hearing loss. Cerebral MRI and CT
scan were normal, as well as nerve conduction studies. We
observed the patient when she was 7 years old and her
neurological examination was essentially normal except for the
optic atrophy and hearing loss. Basal serum lactic and pyruvic acid
were normal. A new audiometric exam confirmed the senso-
rineural hearing loss. Electroencephalogram (EEG) and EKG were
normal. Except for her father there are no other family members
being affected by visual and hearing loss, nor other neurological
symptoms.
Case 1 (Family 2, IV-2)
This 59-year-old proband belongs to an Italian family with at least
other six affected individuals with autosomal-dominant transmis-
sion of optic atrophy. He has suffered a slowly progressive visual
loss since childhood, initially prevalent on the right eye. We
observed this patient when he was 57 years old and his
neurological examination was remarkable only for bilateral optic
atrophy and diffusely weak deep tendon reflexes. Serum lactic acid
after standardized exercise was abnormally elevated (37.6mg/dl,
normal values522). Muscle biopsy showed non-specific signs of
myopathy (Fig. 2, panels D, E and F), but electron microscopy
revealed paracristalline inclusions in mitochondria. Audiometric
exam was essentially normal as well as BAEPs. PVEPs showed
markedly reduced amplitudes and increased latencies of cortical
responses. The electroretinogram was unremarkable. Ophthal-
mologic investigations showed reduced visual acuity (2/10 OD,
6/10 OS), pale optic discs at fundus and a central scotoma at
visual field exam.
Case 1 (Family 3, II-1)
The case of this 39-year-old French woman has already been
reported (Amati-Bonneau et al., 2003, 2005) but at that time we
had no information on the muscular pathology. Briefly, she
presented with optic atrophy at the age of 6 years and with
moderate sensorineural hearing impairment since the age of 15
years. Neurophysiological studies (BAEPs and evoked otoacustic
emissions) suggested that deafness was caused by auditive
neuropathy. At a recent neurological examination she showed
severe optic atrophy and deafness and mild ataxia with positive
Romberg sign. She underwent muscle biopsy that showed evidence
of RRFs and COX negative fibres (Fig. 2, panels G, H and I).
Case 1 (Family 4, I-2)
This patient and her daughter were also previously reported
(Amati-Bonneau et al., 2005). Briefly she is a 57-year-old Spanish
woman who has been diagnosed with optic atrophy at age 13 years
and a moderate sensorineural hearing loss was found when she
was 30 years old. The first audiogram at 33 years of age showed a
predominant high-frequency hearing loss, and she displayed a
progressive worsening of auditory function over the following
years. At age 56 years, she complained of exercise intolerance andTa
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EMG documented both myopathy and peripheral neuropathy. She
underwent muscle biopsy, which revealed RRFs and COX negative
fibres. Muscle respiratory chain enzyme activities were essentially
normal, even if on the low side of the control range (data not
shown). She now suffers of bilateral ptosis and ophthalmoplegia,
hypotiroidism, dysphagia and slight cognitive impairment.
Case 2 (Family 4, II-1)
The daughter of the proband of Family 4 was also diagnosed with
optic atrophy and hearing loss at age 9 years. Her clinical
condition is now slowly progressing.
Case 1 (Family 5, II-1)
This 43-year-old man from southern France suffered visual
impairment since childhood and diffuse myalgia in both legs
since adolescence. At age 39 years he experienced gait difficulties
and ataxia was reported at neurological examination. At age 42
years, he was admitted to a gastroenterology unit for an episode of
colic occlusion without any evident mechanical cause and was
thereafter admitted in the neurology unit. At this time, his visual
acuity was reduced to counting fingers in both eyes and fundus
examination showed bilateral optic atrophy. At neurological
examination he also had bilateral ptosis and ophthalmoplegia,
impaired sensation to all modalities predominantly in the lower
limbs, marked gait ataxia and positive Romberg sign.
Neurophysiological studies (BAEPs and evoked otoacustic emis-
sions) showed auditive neuropathy. EMG revealed an axonal
sensory-motor neuropathy without clear evidence of myopathy.
Muscular biopsy evidenced RRFs and COX negative fibres. Brain
MRI revealed an atrophy of the corpus callosum and brainstem
and a mild cerebellar atrophy (Fig. 3, panel D). Furthermore,
bilateral basal ganglia hypointensity was detected at T2-weighted
MRI scan (Fig. 3, panels E and F). Interestingly, brain MRS was
normal, notably the lactate content (data not shown). The family
history of this proband was remarkable for optic atrophy in his
mother and brother, but we did not obtain further details from
these cases.
Case 1 (Family 6, II-8)
This 67-year-old man from western France had bilateral ptosis and
moderate hearing loss since childhood. At age 60 years, he
developed bilateral cataract requiring surgery. At age 67 years, he
was admitted in a neurological unit complaining muscular
weakness. At neurological examination he had bilateral ptosis
Fig. 2 Muscle histopathology (Gomori modified trichrome, COX/SDH and SDH stain). (A), (B) and (C) refer to the proband of Family 1.
In panel A two fibres displaying increased eosinofilic material with subsarcolemmal distribution, which resemble RRFs are shown (asterisks).
In panel B, at the double COX/SDH stain some COX-deficient fibres are recognized by the prevalent SDH violet stain (arrows), and one
hyperintense SDH fibre is also shown (asterisk). In panel C, a section serial to the previous in panel B shows numerous fibres with increased
SDH stain, in particular in the subsarcolemmal region (arrows). (D), (E) and (F) refer to the proband of Family 2. In panel D a hypertrophic
fibre is shown with numerous centralized nuclei (arrows), whereas this patient did not present RRFs. Panels E and F also show the great
variability of fibre size, but no clear COX-deficient or hyperintense SDH fibres were present.However, a prevalent SDH stain was frequent
in some fibres at COX/SDH double stain, as well as some parcellar increase of SDH only stain was evident in a few fibres. (G), (H) and (I)
refer to the proband of Family 3. In panel G a typical RRFs is shown (asterisk). In panel H frequent COX-deficient fibres are seen (arrows),
and in panel I increased subsarcolemmal staining of SDH is present in numerous fibres (arrows).
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and ophthalmoplegia, mild optic atrophy and areflexia at four
limbs. Muscular CPK as well as blood and CSF lactate levels were
normal. EMG revealed an axonal sensory-motor neuropathy and
myopathic involvement of orbicularis oculi muscle. Muscular
biopsy evidenced numerous RRFs and COX negative fibres and
electron microscopy revealed paracristalline inclusions in mito-
chondria. The family history of this patient was remarkable for
ptosis in his father, sister and brother but no further clinical
details were available on these patients.
Muscle histopathology and ultrastructure
Quadriceps, deltoid, or tibialis anterior muscle biopsies, either by
needle or open surgery, were performed under local anaesthesia
and after informed consent of the patient. Muscle specimens were
frozen in cooled isopentane and stored in liquid nitrogen for
histological and histoenzymatic analysis including Gomori mod-
ified trichrome staining, COX activity, succinate dehydrogenase
(SDH) activity and double COX/SDH staining according to
standard protocols. A fragment was also fixed in 2% glutaralde-
hyde and processed for ultrastructural analysis.
Fibroblasts culture
Fibroblasts culture was established from skin biopsies, having
obtained informed consent of the patient. Fibroblasts were grown
in DMEM medium supplemented with 10% fetal bovine serum
(FBS), 2mM l-glutamine and antibiotics. For the experiments,
fibroblasts were grown in DMEM glucose medium or DMEM
glucose-free medium containing 5mM galactose, 5mM pyruvate
(DMEM galactose medium). Mitochondrial morphology was
assessed after cell staining with 10 nM Mitotracker (Molecular
Probes) for 30min at 37C. Fluorescence was visualized with a
digital imaging system using an inverted epifluorescence micro-
scope with 63/1.4 oil objective (Diaphot, Nikon, Japan). Images
were captured with a back-illuminated Photometrics Cascade CCD
camera system (Roper Scientific, Tucson, AZ, USA) and
Metamorph acquisition/analysis software (Universal Imaging
Corp., Downingtown, PA, USA).
Molecular investigations
Informed consent for genetic investigations was obtained from all
patients after approval of the study by the board of the local
ethical committee in the different institutions participating to this
project. Total DNA was extracted from the platelet/lymphocyte
fraction and skeletal muscle by the standard phenol/chloroform
method.
Sequencing of the OPA1 gene
For the OPA1 gene analysis genomic DNA was amplified by PCR
with specific primers designed to amplify all exons and flanking
intronic regions as previously described (Pesch et al., 2001).
PCR reactions were carried out in a 50 ml volume with 50–100 ng
genomic DNA, 10mM Tris–HCL pH 8.9, 50mM KCL, 1,5-3mM
MgCl2 and 200 mM of each dNTP, 10 pmol of primers and 1U
AmpliTaq polymerase (Applied Biosystems, Weiterstadt, Germany).
A B C
D E F
Fig. 3 Brain MRI and CTscan. (A), (B) and (C) refer to the proband from Family 1. In panel A a mid-sagittal T1-weighted brain MRI scan
shows variable degrees of atrophy affecting cerebral cortex, brainstem and cerebellum. In panel B the axial gradient echo MRI scan shows
bilateral hypointensity within the globi pallidi (arrows), which is detected as depositions of calcium in the CTscan (arrows) shown in
panel C. (D), (E) and (F) refer to the proband from Family 5. In panel D a mid-sagittal T1-weighted brain MRI scan shows a thin corpus
callosum as well as brainstem and cerebellar atrophy. In panel E the axial T2-weighted scan shows bilateral hypointensity within the globi
pallidi, which are also detected in the coronal scan (arrows) shown in panel F.
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PCR products were purified by ExoSAP treatment (Amersham)
and sequenced employing BigDye Terminator chemistry (Applied
Biosystems).
Analysis of mtDNA deletions
Southern blot analysis was performed, as previously reported
(Moraes et al., 1989), on the linearized mtDNA molecule after
digestion with the restriction enzyme PvuII, separated by agarose
electrophoresis (0.8%), transferred onto nitrocellulose membranes
and hybridized with the entire human mtDNA probe labelled
with digoxigenin-alkaline phosphatase (Roche Diagnostics,
Switzerland).
Long-range PCR on mtDNA was also performed by two
different protocols. One method is essentially as reported by
Nishigaki et al. (2004). The set of primers used is as follows:
F1482-1516 and R1180-1146 (wild-type mtDNA fragment of
16.267 bp) F3485-3519 and R14820-14786 (wild-type mtDNA
fragment of 11.335 bp), F5459-5493 and R735-701 (wild-type
mtDNA fragment of 11.845 bp). The PCR conditions were: one
cycle at 94C for 1min; 30 cycles at 98C for 10 s and 68C for
11min; a final superextension cycle at 72C for 10min. The PCR
was performed using Takara LA Taq DNA polymerase for the first
pair of primers, and Takara Ex Taq DNA polymerase for the other
set of primers (Takara Shuzo Corp., Japan). The PCR products
were separated by a 0.8% agarose gel. The second method is just
similar to the one previously described, the PCR being performed
by using Takara LA Taq DNA polymerase (Takara Shuzo Corp.,
Japan) and two set of primers: F8285-8314 and R15600-15574
(wild-type mtDNA fragment of 7315 bp); F8285-8314 and R13705-
13677 (wild-type mtDNA fragment of 5420 bp). The PCR
conditions were one cycle at 94C for 2min; 30 cycles at 98C
for 5 s and 68C for 15min; a final superextension cycle at 72C
for 10min.
Sequencing of mtDNA
The complete mtDNA was amplified in 24 overlapping PCR
fragments using specifically designed primers (available upon
request) based on the revised human mtDNA Cambridge reference
sequence (www.mitomap.org/mitoseq.html) (Andrews et al.,
1999). The PCR fragments were sequenced in both directions
using a dye terminator cycle sequencing kit (Applera, Rockville,
MD). Assembling and identification of variations in the mtDNA
was carried out using the Staden Package (Staden et al., 2000).
Sequencing across the junction points of some mtDNA
deletions was achieved by amplifying specific mtDNA fragments
to detect the 5 kb deletion, using the set of primer F8287-8306 and
R13590-13571, and the 8.1 and 7.6 kb deletion using the set of
primer F5651-5670 and R14268-14249. The PCR conditions
were: one first cycle at 94C for 5min; 30 cycles at 94C for
1min, 55C for 1min, 72C for 1min; a final superextension cycle
at 72C for 7min. The PCR products, isolated from the agarose
gels by QIAquick gel extraction kit (Qiagen, Valencia, CA),
were sequenced in an ABI Prism 310 Genetic Analyzer using Big
Dye Terminator Cycle Sequencing Reaction Kits (Applied
Biosystems).
Evaluation of mtDNA copy number
Quantitation of mtDNA relative to nuclear DNA (nDNA)
was performed by two real-time PCR-based different methods.
Both were multiplex assays based on hydrolysis probe chemistry.
In the first method the target genes were the 12S ribosomal gene
of mtDNA (primers and probe sequences and PCR reaction
conditions are available on request) and the RNAseP nuclear gene
(TaqMan RNAseP Control Reagent Kit, Applied Biosystems,
Foster City, CA, USA). Calibration curves were used to quantify
mtDNA and nDNA copy number, which were based on the linear
relationship between the crossing points cycle values and the
logarithm of the starting copy number.
The second method was as previously described (Cossarizza
et al., 2003). Briefly, a mtDNA fragment (nt 4625-4714) and a
nuclear DNA fragment (FasL gene) were co-amplified by multi-
plex polymerase chain reaction. PCR reaction conditions, primers
and probes are as previously detailed (Cossarizza et al., 2003).
A standard curve for mtDNA and nuclear DNA was generated
using serial known dilutions of a vector (provided by Genemore,
Modena, Italy) in which the regions used as template for the two
amplifications were cloned tail to tail, to have a ratio of 1:1 of the
reference molecules.
For both methods the data are means of at least three
independent measurements.
Sequencing of nuclear genes involved in mtDNA
multiple deletions
Direct sequencing of the complete coding region and the exon/
intron boundaries of the genes POLG1, PEO1 (Twinkle) and
SLC25A4 (ANT1) were carried out as previously described
(Gonza`lez-Vioque et al., 2006) in an ABI 3730 (Applied
Biosystems, Foster City, CA, USA) sequencer.
OPA1protein homology modelling
The OPA1 sequence (gi:18860834;NM_130833.1), was submitted
to profile–profile sequence searches with the FFAS (Jaroszewski
et al., 2002) server (http://ffas.ljcrf.edu). Bacterial dynamin like
protein (BDLP GI:122920796) was identified as the most
significant hit (FFAS score -44.1) with a sequence identity of
13% in the region of 220-940 of OPA1. The BDLP coordinates
(PDB-ID 2j68) (Low and Lowe, 2006) were used as a template for
modelling the OPA1 structure with the SCWRL-Server (http://
www1.jcsg.org/scripts/prod/scwrl) using default settings with
conformations of conserved residues retained. Manual inspection,
mutagenesis and figures were done using program PyMOL
(DeLano Scientific).
Statistics
Data were analysed by one-way ANOVA, using the software
SigmaStat Ver. 3.5 (Systat Software Inc.). Data were considered
significantly different when P-values50.05.
Results
Mutation analysis of OPA1 gene
All six probands with optic atrophy ‘plus’ clinical
phenotypes underwent complete sequence analysis of the
OPA1 gene and in each case a mis-sense pathogenic
mutation was found. Sequencing of the mutated exon was
performed in other members of the family, when available,
and revealed a full penetrance of the mutated alleles in
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other affected patients. The mutation c.1316 G4T
(p.G439V) in exon 14, found in Family 1, was previously
reported and molecular analysis of multiple family
members demonstrated that the mutation was present
only in the proband and her daughter suggesting a de novo
event (Liguori et al., in press). The mutation of Family 1 is
close to the previously reported mutation c.1334 G4A
(p.R445H) in exon 14 (Treft et al., 1984; Meire et al., 1985;
Shimizu et al., 2003; Amati-Bonneau et al., 2003; Payne
et al., 2004), which was found in Family 3 and Family 4 of
our series. Both these mutations, as well as the others
identified in Family 5 (c.1635 C4G, p.S545R, exon 17) and
Family 6 (c.1069 G4A, p.A357T, exon 11), introduce
amino-acid changes in highly conserved positions of the
GTPase domain and were not found in a panel of 460
control chromosomes. The mutation found in Family 5,
which is of French ancestry, has also been detected in an
unrelated pedigree from the United Kingdom displaying
a similar clinical phenotype (Hudson et al, in this issue).
Furthermore, this same mutation has also been previously
found in a study on a series of DOA patients from Japan
(Nakamura et al., 2006). Finally, the c.2729 T4A
(p.V910D) mutation in exon 27 found in Family 2,
stands out because it affects the GTPase effector domain
and is associated with a milder phenotype compared to all
other mutations (Table 1).
Muscle histochemistry and ultrastructure
All probands from the six families here reported underwent
skeletal muscle biopsy and in all occasions, except for case 1
from Family 2, RRFs and/or COX negative fibres were
detected at Gomori-modified trichrome and double COX/
SDH staining (Table 1 and Fig. 2, panels A, B, G and H).
SDH staining also showed different degrees of mitochon-
drial proliferation ranging from increased subsarcolemmal
staining to full SDH positive fibres (Fig. 2, panels C and I).
Case 1 from Family 2 again stands out because he did not
display any clear sign of mitochondrial dysfunction at
muscle histochemistry, even if a frequent prevalence of the
SDH stain was observed at double COX/SDH staining,
possibly indicative of a partially depleted COX activity
(Fig. 2, panel E). However, this patient had non-specific
histological changes, such as marked variability of fibres size
with both hypo and hypertrophic changes, splitting fibres,
central nuclei and sporadic subsarcolemmal rimmed
vacuoles, all suggestive of myopathy (Fig. 2, panels D
and F). He underwent muscle biopsy because of pathol-
ogical serum lactate levels after standardized muscle exercise
(see case report). Overall, the patients of our case series
ranged between age 38 and 67 years and, with the exception
of case 1 from Family 2, RRF were 2.5 to 8%, SDH
hyperintense fibres were 6 to 35%, and finally COX
negative fibres were 7 to 35%. In all cases who underwent
electron microscopy there was ultrastructural evidence of
mitochondrial pathology, including the proband from
Family 2, most frequently mitochondrial proliferation,
altered morphology of mitochondria and cristae organiza-
tion, and paracristalline inclusions (Fig. 4).
Mitochondrial DNA analysis
The finding of clear signs of mitochondrial myopathy, with
a mosaic distribution of RRFs and COX negative/SDH
hyperintense fibres pointed to the possible occurrence of
mtDNA defects and prompted various molecular investiga-
tions on mtDNA. Initially, due to the apparent maternal
inheritance, the index case of Family 4 underwent a
complete sequence analysis of muscle mtDNA, which did
not reveal any candidate pathogenic mutation. All changes
detected were well established population-specific poly-
morphic variants defining haplogroup J1 and the complete
sequence has been deposited in GenBank [http://
www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html
(accession number is EU151466)]. None of the other
probands underwent complete mtDNA sequence analysis,
mostly because of unequivocal evidence of dominant
transmission of the disease, as in Families 1, 2 and 6.
All probands underwent mtDNA analysis to screen for
the presence of large-scale rearrangements, either by
Southern blot analysis followed by long PCR, or directly
by long-range PCR when the availability of muscle mtDNA
was limited. All probands who underwent Southern blot
analysis (Families 3, 4, 5 and 6) showed variable levels of
mtDNA multiple deletions (one example is given in Fig. 5,
panel A). The presence of multiple deletions was confirmed
in all probands by long-range PCR performed with different
sets of primers (Fig. 5, panels B and C). We did not
perform quantitative analysis, but the abundance of multi-
ple deletions was quite variable ranging from patients with
very low levels (Fig. 5, line 1 in panel C) to cases with
Fig. 4 Ultrastructure of skeletal muscle. At electron microscopy, a
collection of aberrant subsarcolemmal mitochondria is recogniz-
able, with ‘parking lot’-like paracristallin inclusions, in the muscle
biopsy from the proband of Family 6.
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higher abundance (Fig. 5, line 4 in panel C). To confirm
that the bands detected by long-range PCR were truly
deleted molecules of mtDNA, we specifically re-amplified
by PCR with appropriate primers some of the putative
deletions, purified the band and performed sequence
analysis detecting the junction point of the deleted molecule
(Fig. 6). The proband from Family 4 was not investigated
by this approach, because muscle DNA was no longer
available. We detected the mtDNA 4.9 kbp (common
deletion) in all the other probands investigated (the same of
panel C in Fig. 5).The mtDNA 8.1 kbp was particularly
abundant in proband 1 from Family 2, but present only at
low level in all other cases, whereas the mtDNA 7.6 kbp
was easily detected in all probands except the one from
Family 2.
The absolute quantitation of mtDNA copy number
was performed on DNA samples extracted from skeletal
muscle of the six probands and of 14 normal individuals
(Fig. 7). As negative and positive controls we respec-
tively used total DNA extracted from 143B.TK-derived
209 Rho 0 cells (a kind gift of Giuseppe Attardi),
completely devoid of mtDNA, and from skeletal muscle
of a patient with mitochondrial encephalomyopathy, lactic
acidosis and stroke-like (MELAS) syndrome with abundant
RRFs and over 80% heteroplasmy of the 3243A4G
tRNALeu mtDNA point mutation (Valerio Carelli, data
not shown).
The mean values of mtDNA copy number in control
groups were 1949 948 (age-matched controls) and
2008 927 (total controls). We found similar values in
affected individuals, except for the probands of Families 3
and 6 that showed a non-significant increase of mtDNA
copy number compared to the control group, respectively
3185 1431 and 2954 1033 (Fig. 7).
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Fig. 5 Molecular investigation. (A) Southern blot analysis (proband from Family 4). Lanes1 and 2 are muscle DNAs from two age-matched
healthy controls, who show the presence of a single band correspondent to wild-type mtDNA. Lane 3 is muscle DNA from the proband of
Family 4, showing multiple bands: the wild-type mtDNA and at least other two lighter bands of very low intensity corresponding to
deleted mtDNA molecules. Lane 4 is muscle DNA from a patient with a single large-scale mtDNA deletion. Arrows indicated mtDNA
deleted molecules. (B) Long PCR (proband from Family 4). This panel shows an agarose electrophoresis separation of the wild-type
mtDNA long-PCR amplified fragment of 5420bp on the left, and the fragment of 7315bp on the right (see ‘Methods’ section for details).
Lane1 shows wild-type and deleted molecules of muscle mtDNA from a patient known to carry mtDNAmultiple deletions as detected by
Southern-blot (positive control); Lane 2 shows a single wild-type mtDNA band amplified from muscle DNA of a healthy individual
(negative control); Lane 3 shows a single wild-type mtDNA band amplified from fibroblast DNA of the proband from Family 4; Lane 4
shows wild-type and deleted molecules in the muscle mtDNA of the proband from Family 4. (C) Long PCR (probands from all other
families).This panel shows an agarose electrophoresis separation of the wild-type mtDNA long-PCR amplified fragment of 11.335bp on the
left, and the fragment of 11.845bp on the right (see ‘Methods’ section for details).Variably abundant extrabands due to mtDNA deleted
molecules frommuscle DNA of all probands except the one from Family 4 are present. Lane1 is proband from Family 2; Lane 2 is proband
from Family 1, Lane 3 is proband from Family 5, Lane 4 is proband from Family 3, Lane 5 is proband from Family 6 in both left and right
electrophoresis; in the right electrophoresis Lane 6 is a positive control (a CPEO patient previously diagnosed with mtDNA multiple
deletions) and Lane 7 is a negative control. Molecular weight is marker X (Roche) and the size of some reference bands is indicated.
The presence of mtDNA deletions in all these probands has been further confirmed using the other set of primers described in the
methods (not shown).
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Mitochondrial network in fibroblasts
Considering that OPA1 function is thought to be relevant
for mitochondrial network organization, we investigated the
mitochondrial morphology of fibroblasts bearing the OPA1
mis-sense mutation c.1316 G4T (p.G439V) in exon 14
(proband from Family 1) (Liguori et al., in press) compared
with fibroblasts obtained from normal individuals, in
glucose medium and after 24 h incubation in glucose-free
medium containing galactose. Under this latter condition
cells are forced to rely predominantly on oxidative
phosphorylation for ATP synthesis, given the low efficiency
of this carbon source to feed the glycolytic pathway (Ghelli
et al., 2003). After loading with Mitotracker Red and
examination by fluorescence microscopy, fibroblasts from
control subjects displayed a typical filamentous intercon-
nected network in both growth conditions, with glucose
medium and after 24 h switch on galactose medium
(Fig. 8). The OPA1 mutant fibroblasts presented with
filamentous mitochondria, but less interconnected and
occasionally with balloon-like enlargements, in glucose
medium (Fig. 8). After 24 h growth in galactose medium
the mitochondrial network of most OPA1 mutant fibro-
blasts underwent a complete fragmentation resulting in only
non-interconnected discrete organelles (Fig. 8).
Fig. 6 mtDNA junction points. The deletion junctions of three different mtDNA deletions (4.9kbp or common deletion in the proband
from Family 1; 8.1kbp in the proband from Family 2; 7.6kbp in the proband from Family 5) amplified from muscle DNA and directly
sequenced are shown.The arrows on the sequence pherograms delimitate the repeat location at the boundaries of each mtDNA deletion
and corresponding nucleotide positions are also indicated.
0
2000
4000
6000
8000
10000
12000
m
tD
N
A
 c
op
y 
nu
m
be
r/n
uc
le
us
Age-matched controls (n=5) Controls (n=14) C.2729 T>A (p.V910D)
C.1316 G>T (p.G439V) C.1635 C>G (p.S545R) C.1334 G>A (p.R445H)
C.1069 G>A (p.A357T) Positive control (MELAS patient)
Negative control (Rho 0 cell line)
Fig. 7 mtDNA content assay. The assessment of muscle mtDNA
copy number of OPA1patients is shown in comparison with normal
controls (age-matched and not) and with positive (a patient with
MELAS syndrome with abundant RRFs) and negative (143B.TK-
derived 209 Rho 0 cells; arrow) controls. Represents a P-value
50.05, the arrow indicates the negative control.
Fig. 8 Mitochondrial network in fibroblasts. The mitochondrial
network of fibroblasts, as visualized by the Mitotracker Red dye,
is shown comparing a control subject with the proband from
Family 1at time 0 in glucose medium, and after 24h growth in
galactose medium.The two conditions do not influence the
interconnected tubular organization of the filamentous
mitochondrial network in the control fibroblasts. The patient’s
fibroblasts present less interconnected filamentous mitochondria
in glucose medium and after 24h growth in galactose medium
the mitochondrial network is completely fragmented.
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Fibroblast cells from Families 3 and 4 patients (Table 1)
were previously investigated and shown to display similar
propensity to hyperfragmentation of mitochondrial network
(Amati-Bonneau et al., 2005).
Exclusion of nuclear genes involved in
mtDNAmultiple deletions
To rule out the contribution of the genes known to be
involved in mtDNA multiple deletion formation we
performed their sequence analysis. No sequence changes
of pathogenic significance were identified in the coding
regions and flanking exon–intron boundaries for POLG1,
PEO1 and SLC25A4, excluding any involvement of these
genes in the pathogenic mechanisms.
OPA1 protein modelling
Sequence searches indicate that OPA1 is a 961 amino acid
residue protein belonging to a family of highly conserved
GTPases related to Dynamin and the closest structural
homologue identified to date is the bacterial dynamin-like
protein (BDLP) (Low and Lowe, 2006). The BDLP structure
provides an OPA1 homology model for the C terminal region
of the transmembrane helix and the PARL cleavage site
(residues 220–960). Currently, OPA1 is considered a
mechano-enzyme that uses GTP hydrolysis to switch between
distinct conformations implicated in membrane fusion.
Except one, all OPA1 mis-sense mutations found in the
DOA patients here investigated reside in the highly conserved
GTPase domain (Fig. 9). GTPase activity is critical for OPA1
function and these miss-sense mutations (A357T, G439V,
R445H, S545R) affect the GTPase domain just adjacent to its
active site potentially impairing GTP hydrolysis by locking
the protein in an ‘on’ or ‘off ’ state. Thus, these mutations
may interfere with nucleotide binding and alter the affinity
and hydrolysis rate of the GTPase domain. Overall, these
mutations possibly impair the fine tuned conformational
states of the active–inactive balance of OPA1, directly
impacting on its properties. The only mis-sense mutation
differently located (V910D) resides outside the GTPase
domain, at the interface of the two effector domains
performing the conformational change (Fig. 9). This muta-
tion replaces a hydrophobic valine with a negatively charged
aspartate and may impact the integrity of the interface by
destabilizing the ‘off ’ state leading to an activated conforma-
tion of the protein.
Discussion
In this study we show the unprecedented finding that
mutations in the OPA1 gene, not predicted to produce pro-
tein truncation and haploinsufficiency as patho-mechanism
for DOA, are associated with mtDNA instability and result
in complicated clinical phenotypes that we propose to
define as OPA1 ‘plus’ syndromes. These clinical phenotypes
seem to be invariably defined at least by the association of
optic atrophy and muscular involvement, which may range
from non-specific myopathy to classical mitochondrial
myopathy with RRFs and COX negative fibres and CPEO,
and in all cases except for Family 2 also by the occurrence
of sensorineural deafness. Central and peripheral nervous
system may also be variably involved, with frequent
occurrence of cerebellar or spinocerebellar ataxia and
peripheral axonal neuropathy. The common molecular
feature we have found in all cases is the accumulation of
multiple mtDNA deletions in the skeletal muscle from these
patients. The age of the patients we have investigated
ranged between 38 and 67 years, thus excluding that the
amount of RRF/COX negative fibres and the levels of
mtDNA multiple deletions we observed could be ascribed
to their age-related somatic accumulation (Johnston et al.,
1995; Bua et al., 2006). Our findings link for the first time
OPA1 protein function with mtDNA integrity maintenance,
making OPA1 the fifth gene involved in mtDNA multiple
deletion pathologies, together with POLG1, PEO1
(Twinkle), SLC25A4 (ANT1) and TP.
OPA1 is a 960 amino acid residue protein that belongs to
a family of highly conserved GTPases related to Dynamin
(Praefcke and McMahon, 2004; Hoppins et al., 2007).
OPA1 is anchored to the mitochondrial inner membrane
and has an important role in the mitochondrial fusion
Fig. 9 OPA1model and DOA mutations. Homology model of
human OPA1 (gi|18860834|ref |NM_130833.1|), residues 220^960,
based on the crystal structure of bacterial dynamin like protein
(PDB-ID 2j68 (Low and Lowe, 2006), FFAS (Jaroszewski et al.,
2002) score -44.1, sequence identity 13%).OPA1 is shown as a grey
cartoon with the GDP molecule bound to the GTPase domain
depicted in sticks. The DOA mutations A357T,G439V, R445H,
S545R and V910D are depicted in sphere mode with carbon atoms
in yellow.
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process and in protection from apoptosis. Indeed, down-
regulation of OPA1 using specific small interference RNA
leads to fragmentation of the mitochondrial network
concomitantly to dissipation of the mitochondrial mem-
brane potential and to a drastic disorganization of the
cristae (Olichon et al., 2003). Moreover, OPA1 is also
involved in protection from and regulation of the apoptotic
process, by dealing with cytochrome c storage and release
(Olichon et al., 2003; Frezza et al., 2006). Recent studies
point to a mounting evidence that OPA1 is also involved in
OXPHOS efficiency (Lodi et al., 2004; Amati-Bonneau
et al., 2005), even if details of its mechanism and role in
mitochondrial respiratory functions are lacking. One
possibility is the involvement of OPA1 in regulating the
amount of mtDNA, as suggested by a study showing that
DOA patients may have slightly reduced mtDNA copy
number in blood lymphocytes (Kim et al., 2005). It is also
known that mutant Mgm1 protein, the homologous protein
of OPA1 in yeast, may lead to loss of mtDNA and petit
phenotype (Herlan et al., 2003). However, our current
results on the possible involvement of OPA1 also in
mtDNA maintenance in human subjects failed to reveal
mtDNA depletion in the skeletal muscle of our probands,
besides the documented occurrence of mtDNA instability
with multiple deletions. On the contrary, in two cases the
mtDNA copy number was increased compared with
controls, even if without reaching statistical significance,
in accordance with the presence of RRFs and compensatory
enhancement of mitochondrial biogenesis.
It is remarkable that, contrary to the majority of the
OPA1 mutations associated with DOA to date, all the
mutations investigated in the present study are mis-sense
point mutations changing amino acid residues in the highly
conserved GTPase domain, with only one exception
(V910D). This rules out haploinsufficiency as a patho-
mechanism in our cases, and suggests more likely that gain
or loss of function of the protein activity is responsible for
mtDNA instability. The current hypothesis states that OPA1
is a mechano-enzyme that uses GTP hydrolysis to switch
between distinct conformations that either facilitate mem-
brane fusion directly or recruit machinery for it (Praefcke
and McMahon, 2004; Olichon et al., 2006; Hoppins et al.,
2007). GTPase activity is critical for OPA1 function and
DOA miss-sense mutations found in the GTPase domain
adjacent to its active site (A357T, G439V, R445H, S545R)
may impair GTP hydrolysis locking the protein in an ‘on’
or ‘off ’ state. Thus, these mutations have the potential to
interfere with nucleotide binding and affinity, possibly
affecting the hydrolysis rate of the GTPase domain. Hence,
these mutations may alter the finely tuned conformational
states of the active–inactive balance of OPA1 protein and have
a direct impact on its properties. The other DOA miss-sense
mutation, i.e. V910D in the GTPase effector domain,
points to the existence of further such critical residues in
the OPA1 protein. Knowing the possible involvement of
dNTP pools in the mtDNA deletion formation in TP
(Nishino et al., 1999), and possibly in ANT1 (Kaukonen
et al., 2000) related syndromes, a scenario we may
hypothesize, based on the currently reported OPA1 defects,
is that differences in GTPase activity of OPA1 may affect the
dGTP pool, ultimately leading to mtDNA instability.
However, OPA1 is attached to the inner mitochondrial
membrane pointing towards the intermembrane space with
a crucial, well-established role in cristae conformation
(Olichon et al., 2003, 2006; Frezza et al., 2006). mtDNA
nucleoids (Malka et al., 2006) are also anchored to the same
inner mitochondrial membrane but on the matrix side.
Thus, the other possible mechanism through which OPA1
mis-sense mutations may lead to mtDNA instability is
either the indirect interaction through changes in cristae
morphology or the direct interaction of OPA1 protein
through its N-terminal matrix-tail with mtDNA nucleoids
and its possible role in stabilizing them. It is reasonable to
predict that shifting the mitochondrial network organiza-
tion towards a more fragmented conformation, as shown by
our investigation on fibroblasts from four patients reported
in the current and previous studies (Amati-Bonneau et al.,
2005), may also imply changes in the cristae organization
and stabilization of mtDNA nucleoids, as well as their
actual amount. Comparatively to other tissues, the skeletal
muscle mitochondrial network is differently organized and
specific studies investigating the fission/fusion activity in
this tissue are lacking. Muscle cells are a syncytium with
mitochondria being intercalated among the myofibres and
abundantly located subsarcolemmally, the site where
mitochondria increase in numbers when compensatory
proliferation occurs in mitochondrial disorders. Our
electron microscopy images of muscle mitochondria show
some of the classical changes previously reported in
mitochondrial myopathies, but these are most probably
due to the accumulation of mtDNA deletions and not
primarily generated by the OPA1 mutations.
The clinical presentation of our patients is similar to
what is usually seen in other mitochondrial encephalomyo-
pathies and more specifically in syndromes related to
mtDNA multiple deletions. These cases widen the pheno-
types that are associated with molecular defects in the
OPA1 gene. The association of CPEO, mitochondrial
myopathy with RRFs and COX negative fibres, cerebellar
or spino-cerebellar involvement, and peripheral neuropathy
has been all previously seen in patients with mutations in
the POLG1 gene (Hudson and Chinnery, 2006). The only
remarkable difference from these clinical phenotypes is the
consistent presence of optic atrophy, as the core clinical
manifestation of any OPA1-related phenotype. We propose
that screening of the OPA1 gene in families with
dominantly inherited CPEO and optic atrophy is manda-
tory, and only further screening of familial CPEO inherited
as a mendelian trait without optic atrophy will provide
evidence if the optic atrophy is a pathognomonic
manifestation of OPA1-related disorders. It is of note that
the only patient with a mutation lying outside the GTPase
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domain (V910D, Family 2) had the milder phenotype
characterized essentially by only optic atrophy as in classic
DOA, but had evidence of myopathy. The latter had no
clear morphologic signs of mitochondrial dysfunction at
muscle histoenzymatic staining, such as RRFs or COX
negative fibres, but had pathologically increased lactic acid
after exercise, mitochondria with paracristalline inclusions
at electron microscopy, and the lowest amount of mtDNA
multiple deletions. Thus, contrary to the truncative
mutations in the OPA1 gene predicted to lead to
haploinsufficiency, which do not present a tight geno-
type–phenotype correlation, we suggest that with OPA1
mis-sense mutations the genotype may be associated with
specific clinical phenotypes. However, it must be noted that
a number of other mis-sense mutations in the OPA1 gene
have been described and listed in the eOPA1 website
(http://lbbma.univ-angers.fr) (Ferre et al., 2005), including
the exons building up the GTPase domain. Concerning
these latter mutations there is no report of ‘plus’ features in
these patients, which seem to be affected by classic DOA.
Thus, it is reasonable to assume that mis-sense mutations
in the GTPase domain not necessarily lead to ‘OPA1 plus’
phenotypes, which may be strictly dependent on amino acid
location and/or change.
Overall, the involvement of OPA1 in mtDNA stability
opens a wide and unexpected scenario, where all the other
proteins involved in the machinery of mitochondrial
fission/fusion may be implicated (Chen and Chan, 2005).
The field of human disorders related to molecular defects in
such proteins is rapidly growing, having at least other three
examples besides OPA1 mutations in DOA: mutations in
the Mfn2 gene causing Charcot–Marie-Tooth (CMT) type
2A dominant peripheral neuropathy (Zuchner et al., 2004),
mutations in the GDAP1 gene causing CMT4A (Niemann
et al., 2005), and the most recently reported first mutation in
the DLP1 gene associated with a lethal infantile neurological
syndrome (Waterham et al., 2007), all these disorders being
frequently if not always associated with optic atrophy.
A further confirmation that fission/fusion machinery may
be very relevant for both mtDNA maintenance and
integrity comes from recent studies on Mfn1 and Mfn2,
as well as OPA1 null cells, suggesting loss of mtDNA
nucleoids and defective oxidative phosphorylation (Chen
et al., 2007).
In conclusion, we report the novel implication of specific
mis-sense mutations in the OPA1 gene in the maintenance
of mtDNA integrity and the association with optic atrophy
‘plus’ syndromes, similar to classic mitochondrial encepha-
lomyopathies. The mechanism leading to mtDNA multiple
deletions is unclear and needs further investigations.
However, the obvious consequence of this report is to
consider OPA1 gene analysis in patients with unexplained
mitochondrial diseases, in particular if optic atrophy is
present and mtDNA multiple deletions are recognized in
the skeletal muscle.
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